Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
Status:
Completed
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
New treatment options are critical for treatment-experienced HIV infected patients with drug
resistance. HIV entry inhibitors have been shown effective in patients with resistance to
other anti-HIV drugs. This study will test the safety and anti-HIV activity of eight
different doses of the HIV entry inhibitor AMD11070 (also known as AMD070) in HIV infected
patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)